Loxo Oncology Inc

Loxo Oncology — Technical Presentation (April 2016)

32 slides from Loxo Oncology's technical presentation, Apr 18, 2016

  1. Slide 1: Disclosure Information: AACR 2016 Author Disclosures

    Disclosure Information AACR 2016 Author Disclosures David S. Hong Travel expenses supported by Loxo Oncology Anna F. Farago None Marcia S. Brose None Howard A. Burris, III None Afshin Dowlati None Todd M. Bauer None Matthew Taylor None Alice T. Shaw None Adriana Estrada-Bernal Research grant from Lo

  2. Slide 2: Kinase Fusions Deserve Our Attention

    Kinase Fusions Deserve Our Attention 3 GENETIC ALTERATION COMMERCIALLY AVAILABLE DRUGS ABL fusion dasatinib, imatinib, nilotinib, ponatinib ALK fusion alectinib, ceritinib, crizotinib BRAF mutation cobimetinib, dabrafenib, trametinib, vemurafenib BRAF fusion cobimetinib, trametinib cKIT mutation das

  3. Slide 3: TRK Fusions are Oncogenic and Signal Through Canonical Downstream Pathways

    TRK Fusions are Oncogenic and Signal Through Canonical Downstream Pathways Normal TRK Proteins Family of neurotrophin receptors TrkA (NTRK1) Pain, thermoregulation TrkB (NTRK2) Movement, memory, mood, appetite, body weight TrkC (NTRK3) Proprioception TRK Fusions Ligand binding domain replaced by 5’

  4. Slide 4: TRK Fusions Found in Diverse Cancer Histologies

    TRK Fusions Found in Diverse Cancer Histologies 5 TRK Fusion Frequency <5% 5–25% >75% CNS Astrocytoma Brain low-grade glioma Glioblastoma GI Colorectal cancer Cholangiocarcinoma GIST Pancreatic cancer Head and neck Squamous cell carcinoma Lung Adenocarcinoma Large cell neuroendocrine Other Acute mye

  5. Slide 5: Enriching for TRK Fusions

    Enriching for TRK Fusions 6 1 Bishop JA et al. Am J Surg Pathol. 2013 Jul;37(7):1053-7. 2 Prasad ML et al. Cancer. 2016 Jan 19. 3 Brenca M et al. J Pathol. 2016 Mar;238(4):543-9. 4 Haller F et al. J Pathol. 2016 Feb 11. Mammary analogue secretory carcinoma1 >50% of nonparotid acinic cell carcinomas

  6. Slide 6: LOXO-101: A Rationally Designed Selective TRK Inhibitor

    LOXO-101: A Rationally Designed Selective TRK Inhibitor 7 Chartier M, Chénard T, Barker J, Najmanovich R. (2013) Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree. PeerJ 1:e126 TRK TRK Highly selective: limited inhibition of other kinases and >1,000x sele

  7. Slide 7: LOXO-101 Phase 1 Study Design

    LOXO-101 Phase 1 Study Design Ongoing dose escalation study Advanced or metastatic solid tumors ECOG 0/1, normal organ function QD or BID oral fixed, continuous dosing, 28-day cycles Outcome measures Safety and tolerability Pharmacokinetics measured at cycle 1, days 1 and 8 Efficacy assessments cond

  8. Slide 8: Baseline Characteristics

    Baseline Characteristics characteristics Subjects (N= 43) Median age (range), years 57.0 (28 – 76) Sex Male / Female 25 (58%) / 18 (42%) Race White / Black / Other 34 (79%) / 6 (14%) / 3 (7%) Tumor Type* Head and neck 8 (19%) Lung 8 (19%) Breast 3 (7%) Colorectal 3 (7%) Pancreatic 3 (7%) ECOG Status

  9. Slide 9: Disposition

    Disposition 10 ALL PATIENTS TRK Fusion Patients TRK MUTATION/ AMPLIFICATION PATIENTS N=43 N=7 N=5 On study 13 (30%) 7 (100%) 2 (40%) Discontinued 30 (70%) 0 (0%) 3 (60%) Reasons for discontinuation Disease Progression 23 (53%) -- 3 (60%) Adverse Event 3 (7%)* -- -- Withdrawal of consent 2 (5%) -- --

  10. Slide 10: Linear PK profile following oral administration shows high plasma exposure and no accumulation

    Linear PK profile following oral administration shows high plasma exposure and no accumulation Slow off-rate; T1/2 = 160 min LOXO-101 Exposure 11 The horizontal line representing TRKA IC90 refers to the total plasma concentration of LOXO-101 that is associated with an unbound concentration of LOXO-1

  11. Slide 11: LOXO-101 Phase 1 Interim Treatment-Emergent AEs

    LOXO-101 Phase 1 Interim Treatment-Emergent AEs, Regardless of Attribution to Study Drug Dose 100 mg BID (n=24) Total (n=43) Adverse Events (AEs)* Gr 3/4 All Gr Gr 3/4 All Gr n (%) n (%) n (%) n (%) Fatigue 0 5 (21%) 2 (5%) 14 (33%) Constipation 0 3 (13%) 1 (2%) 10 (23%) Dizziness 0 6 (25%) 0 10 (23

  12. Slide 12: LOXO-101 Summary of Best Response Data as of March 25, 2016

    LOXO-101 Summary of Best Response Data as of March 25, 2016 13 ALL PATIENTS* TRK Fusion Patients** TRK MUTATION/ AMPLIFICATION PATIENTS N=41 N=6 N=5 CR 0 0 0 PR 5 5 0 SD 7 1 3 PD 23 0 2 Off-study prior to first response assessment 6 0 0 Overall Response Rate 12% (5/41) 83% (5/6) 0% (0/5) * Excludes

  13. Slide 13: Best Response to LOXO-101 for Patients with TRK Fusions

    Best Response to LOXO-101 for Patients with TRK Fusions 14 Note: Ongoing cycle number noted for each patient below each bar; 28-day cycles -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% Maximum Change in Tumor Size (%) Stable disease Confirmed partial response - 30% 7+ 7+ 10+ 10+ 7+ 14+

  14. Slide 14: Patient Cases – TRK Fusions

    PATIENT CASES – TRK FUSIONS 15

  15. Slide 15: Patient #1: LMNA-NTRK1 fusion soft tissue sarcoma

    Patient #1: LMNA-NTRK1 fusion soft tissue sarcoma 42 yo female with undifferentiated sarcoma progressed through epirubicin, ifosfamide, sorafenib, and doxorubicin 100mg BID Rapid resolution of dyspnea and hypoxemia Confirmed partial response Currently on study in cycle 14 Study baseline Study cycle

  16. Slide 16: Patient #2: ETV6-NTRK3 fusion GIST

    Patient #2: ETV6-NTRK3 fusion GIST 55 yo male with GIST progressed through imatinib, sunitinib, sorafenib, nilotinib, and regorafenib 150mg BID Confirmed partial response Currently on study in cycle 10 17 CT PET Study baseline Study cycle 5 day 1 Study baseline Study cycle 3 day 1 Study cycle 9 day

  17. Slide 17: Patient #3: ETV6-NTRK3 fusion MASC of the salivary gland

    Study baseline Study cycle 3 day 1 Study cycle 9 day 1 Patient #3: ETV6-NTRK3 fusion mammary analogue secretory carcinoma of the salivary gland (MASC) 33 yo male progressed through docetaxel, carboplatin and 5FU 100mg BID Confirmed partial response Currently on study in cycle 10 18

  18. Slide 18: Patient #4: ETV6-NTRK3 fusion MASC of the salivary gland

    19 Patient #4: ETV6-NTRK3 fusion mammary analogue secretory carcinoma of the salivary gland (MASC) 66 yo male progressed through radiotherapy, dasatinib, GDC-0941+ erlotinib, and ABBV-399 100mg QD* Confirmed partial response Currently on study in cycle 7 Study baseline Study cycle 3 day 1 Study cycl

  19. Slide 19: Patient #5: ETV6-NTRK3 fusion papillary thyroid cancer

    Patient #5: ETV6-NTRK3 fusion papillary thyroid cancer 20 33 yo male progressed through RAI, pazopanib, trametinib 100mg BID Confirmed partial response Rapid improvement cervical lymphadenopathy Currently on study in cycle 7 Study baseline Study cycle 3 day 1 Study cycle 7 day 1

  20. Slide 20: Patient #6: TPR-NTRK1 non-small cell lung cancer

    Patient #6: TPR-NTRK1 non-small cell lung cancer 21 28 yo male progressed through cisplatin and etoposide 100mg BID 18% reduction; stable disease Patient’s only RECIST evaluable lesions are in the bone Non-target lesion regressions in lung and brain Resolution of cough and pain Currently on study in

  21. Slide 21: Best Response to LOXO-101 for Patients with TRK Fusions

    Best Response to LOXO-101 for Patients with TRK Fusions 22 Note: Ongoing cycle number noted for each patient below each bar; 28-day cycles -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% Maximum Change in Tumor Size (%) Stable disease Confirmed partial response - 30% 7+ 7+ 10+ 10+ 7+ 14+

  22. Slide 22: LOXO-101 Phase 2 Adult Basket Trial

    LOXO-101 Phase 2 Adult Basket Trial Solid tumors, including CNS tumors, with TRK fusion based on local or pre-existing testing Enrolling patients 12 yo; ECOG 0-3 Dose: 100mg BID Primary endpoint: Best ORR Global study (20-30 sites) Patient concierge service for enrollment, including single patient p

  23. Slide 23: TRK Fusions Present Assay Complexity Due to Varied Fusion Partners

    TRK Fusions Present Assay Complexity Due to Varied Fusion Partners 24 KINASE DOMAIN NTRK1/2/3 NTRK1 NTRK2 NTRK3 Selection of fusion constructs shown. Graphic is not comprehensive for all TRK fusion constructs described in the literature. BCAN TPR CD74 CEL IRF2BP2 LMNA MPRIP NFASC SSBP2 TFG TPM3 AFAP

  24. Slide 24: Finding Fusions Requires Careful Assay Design

    Finding Fusions Requires Careful Assay Design NGS, Next-Generation Sequencing RT-PCR, Reverse Transcription Polymerase Chain Reaction FISH, Fluorescence In Situ Hybridization IHC, Immunohistochemistry 25 Assay designs present varied challenges for fusion detection

  25. Slide 25: Different Methods Lead to Variable Estimates of Fusion Frequency, Ex. ALK in NSCLC

    Different Methods Lead to Variable Estimates of Fusion Frequency, Ex. ALK in NSCLC 26 DETECTION TECHNOLOGY ALK FUSION FREQUENCY IN LARGE NSCLC COHORTS REFERENCE DNA NGS (hybrid capture) 4.4% (n=1,070) Ali et al. ASCO 2014 Annual Meeting; Abstract 8049 RNA NGS (amplicon) 4.3% (n=115) Hovelson et al.

  26. Slide 26: Point Estimates of TRK Fusion Frequency Are Similarly Varied

    Point Estimates of TRK Fusion Frequency Are Similarly Varied 27 LUNG CANCER DETECTION TECHNOLOGY TRK FUSION FREQUENCY REFERENCE RNA NGS (anchored multiplex PCR) 2/1,378 (0.1%) Farago et al. J Thorac Oncol. 2015;10: 1670–1674. RNA NGS (RNA-Seq / whole transcriptome) 1/513 (0.2%) Stransky et al. Nat C

  27. Slide 27: Considerations for Patient Screening

    TRK fusions have been identified across multiple tumor types Trend toward younger patients Consider patients lacking other “common” mutations Lung: EGFR-negative, ALK-negative, ROS1-negative, KRAS-negative Colorectal: KRAS-negative, BRAF-negative GIST: KIT-negative, PDGFR-negative Thyroid: BRAF-nega

  28. Slide 28: Acquired Resistance to Kinase Inhibitors

    Universally encountered with targeted therapies As of this presentation, no LOXO-101 responder has progressed Most common: mutations that limit drug binding Gatekeeper: ABL-T315I, EGFR-T790M, ALK-L1196M Solvent front: ALK-G1202R, ROS1-G2032R Case reports: two patients with tumor progression after in

  29. Slide 29: LOXO-195: 2nd Generation TRK Inhibitor

    LOXO-195: 2nd Generation TRK Inhibitor LOXO-101 “like” Highly potent: nanomolar in cell against TRKA, TRKB, TRKC Highly selective: >1,000x selective over other off targets Excellent drug properties: orally dosed, high exposure, low clearance Structural modeling: should be active against acquired res

  30. Slide 30: Conclusions

    Conclusions LOXO-101 is a purpose-built, oral, selective and potent TRK inhibitor PK analyses demonstrate very high Cmax (mean levels >IC90) and linear PK with no significant drug accumulation LOXO-101 is well tolerated, with most common adverse events including Grade 1/2 fatigue, constipation, and

  31. Slide 31: Acknowledgements

    Acknowledgements LOXO-101 patients and their families and caregivers Co-investigators and study support staffs This trial sponsored and supported by Loxo Oncology LOXO-101 and LOXO-195 invented by Array BioPharma 32

  32. Slide 32: Acknowledgements

    Acknowledgements * LOXO-101 patients and their families and caregivers * Co-investigators and study support staffs * This trial sponsored and supported by Loxo Oncology * LOXO-101 and LOXO-195 invented by Array BioPharma 2

Loxo Oncology — Technical Presentation (April 2016) on 6ix